Amgen (Germany) Performance
AMG Stock | EUR 257.85 5.35 2.03% |
The firm shows a Beta (market volatility) of -0.14, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Amgen are expected to decrease at a much lower rate. During the bear market, Amgen is likely to outperform the market. At this point, Amgen Inc has a negative expected return of -0.2%. Please make sure to confirm Amgen's jensen alpha, treynor ratio, and the relationship between the standard deviation and total risk alpha , to decide if Amgen Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Amgen Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Begin Period Cash Flow | 8 B |
Amgen |
Amgen Relative Risk vs. Return Landscape
If you would invest 29,775 in Amgen Inc on September 13, 2024 and sell it today you would lose (3,990) from holding Amgen Inc or give up 13.4% of portfolio value over 90 days. Amgen Inc is currently producing negative expected returns and takes up 2.0122% volatility of returns over 90 trading days. Put another way, 17% of traded stocks are less volatile than Amgen, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
Risk |
Amgen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amgen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amgen Inc, and traders can use it to determine the average amount a Amgen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1015
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | AMG |
Estimated Market Risk
2.01 actual daily | 17 83% of assets are more volatile |
Expected Return
-0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Amgen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amgen by adding Amgen to a well-diversified portfolio.
Amgen Fundamentals Growth
Amgen Stock prices reflect investors' perceptions of the future prospects and financial health of Amgen, and Amgen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amgen Stock performance.
Return On Equity | 1.26 | |||
Return On Asset | 0.0997 | |||
Profit Margin | 0.25 % | |||
Operating Margin | 0.38 % | |||
Current Valuation | 163.09 B | |||
Shares Outstanding | 533.98 M | |||
Price To Earning | 17.42 X | |||
Price To Book | 38.95 X | |||
Price To Sales | 5.08 X | |||
Revenue | 26.32 B | |||
EBITDA | 12.17 B | |||
Cash And Equivalents | 8.08 B | |||
Cash Per Share | 14.23 X | |||
Total Debt | 37.35 B | |||
Debt To Equity | 3.98 % | |||
Book Value Per Share | 6.86 X | |||
Cash Flow From Operations | 9.72 B | |||
Earnings Per Share | 11.41 X | |||
Total Asset | 65.12 B | |||
About Amgen Performance
By analyzing Amgen's fundamental ratios, stakeholders can gain valuable insights into Amgen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Amgen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Amgen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. AMGEN INC operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 24300 people.Things to note about Amgen Inc performance evaluation
Checking the ongoing alerts about Amgen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amgen Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Amgen Inc generated a negative expected return over the last 90 days | |
Over 80.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Amgen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amgen's stock is overvalued or undervalued compared to its peers.
- Examining Amgen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amgen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amgen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amgen's stock. These opinions can provide insight into Amgen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
Global Correlations Find global opportunities by holding instruments from different markets | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |